BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
10 Demonstrated Tips to Expand Your New Android Cell phone: A Thorough Aide - 2Ukraine proved this drone-killer works. Now, the West is giving it a shot.
- 3Ancient eggshells shed new light on crocodiles that hunted prey from trees
- 4The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
- 5Educated: How to Take full advantage of Your Gadgets
- Lilly becomes first healthcare firm to join trillion-dollar club, Wall Street reacts
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- 4K televisions for Extreme Film Watching Experience
- Select Your Go-To Bluetooth Earphones
- A definitive Manual for Picking Electric Vehicle: Decision in favor of Your Number one
- Germany's Bundestag extends two armed forces missions abroad
- Vote In favor of Your #1 Electric Vehicles
- Manual for Tracking down the Mysterious Cascades in China
- Vote In favor of Your Number one Game Control center
